Data comparison in adjuvant melanoma trials | ||||||
---|---|---|---|---|---|---|
Patient population | CM238 [60] | COMBI-AD [61] | KN054 [4] | |||
Completely resected stage IIIB/C or IV melanoma | Completely resected, BRAFV600E/K-positive stage IIIA/B/C melanoma | Completely resected stage IIIA/B/C melanoma | ||||
Treatment | Nivo | Lpi | Dab/Tram | Placebo | Pembro | Placebo |
N | 453 | 453 | 438 | 432 | 514 | 505 |
RFS HR | 0.65 (97.56% CI 0.51–0.83), P < 0.0001 | 0.47 (95% CI 0.39–0.58), P < 0.001 | 0.57 (98.4% CI 0.43–0.74), P < 0.001 | |||
1-year RFS rate (%) | 71 | 61 | 88 | 56 | 75 | 61 |
18-months RFS rate (%) | 66 | 53 | N/A | N/A | 71 | 53 |
3-years OS rate (%) | N/A | N/A | 86 | 77 | N/A | N/A |
Grade 3–5 TRAEs (%) | 14 | 46 | 31 | 5 | 15 | 3 |
DC rate due to AEs (%) | 10 | 43 | 26 | 3 | 14 | 2 |